Carl Dambkowski Sells 10,900 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 10,900 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $75.00, for a total value of $817,500.00. Following the sale, the insider directly owned 271,108 shares in the company, valued at $20,333,100. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The stock was sold at an average price of $55.07, for a total value of $593,929.95.
• On Wednesday, October 1st, Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock. The shares were sold at an average price of $39.80, for a total value of $203,378.00.

Apogee Therapeutics Price Performance

Apogee Therapeutics stock traded up $1.25 during trading hours on Friday, hitting $76.75. The company had a trading volume of 733,690 shares, compared to its average volume of 715,559. Apogee Therapeutics Inc. has a fifty-two week low of $26.20 and a fifty-two week high of $77.09. The firm has a market capitalization of $5.24 billion, a P/E ratio of -17.52 and a beta of 1.41. The firm’s fifty day moving average is $57.59 and its 200-day moving average is $45.43.

Apogee Therapeutics (NASDAQ:APGE) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. Analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its holdings in shares of Apogee Therapeutics by 99.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after purchasing an additional 383 shares during the period. ANTIPODES PARTNERS Ltd grew its position in Apogee Therapeutics by 41.2% during the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after buying an additional 246 shares in the last quarter. Brooklyn Investment Group bought a new position in Apogee Therapeutics during the first quarter valued at about $42,000. AlphaQuest LLC acquired a new position in Apogee Therapeutics in the 1st quarter valued at approximately $43,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock worth $77,000 after acquiring an additional 272 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

Wall Street Analyst Weigh In

APGE has been the subject of several recent research reports. BTIG Research reissued a “buy” rating and issued a $115.00 price target on shares of Apogee Therapeutics in a research note on Thursday, October 9th. Mizuho started coverage on shares of Apogee Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $105.00 target price for the company. Royal Bank Of Canada increased their price target on shares of Apogee Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Monday, November 3rd. Wall Street Zen raised shares of Apogee Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Craig Hallum began coverage on shares of Apogee Therapeutics in a report on Monday, November 3rd. They issued a “buy” rating and a $109.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $98.38.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.